Biopreservation Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[228+ Pages Report] According to Facts & Factors, the global biopreservation market size was estimated at USD 4.68 billion in 2025 and is expected to reach USD 24.57 billion by the end of 2034. The biopreservation industry is anticipated to grow by a CAGR of 14.40% between 2026 and 2034. The biopreservation Market is driven by the rapid expansion of regenerative medicine and the increasing demand for long-term storage of high-value biological samples in biobanks.

Market Overview

Biopreservation refers to the sophisticated process of maintaining the functional integrity, viability, and stability of biological materials such as cells, tissues, organs, and genetic samples outside of their natural environment. This specialized field utilizes a combination of advanced cooling technologies, chemical stabilizers, and controlled-rate freezing to halt metabolic activity without causing cellular damage. By creating a bridge between the collection of biological assets and their eventual therapeutic or diagnostic use, biopreservation serves as a critical pillar for modern biotechnology. It ensures that life-saving materials, including stem cells and engineered tissues, remain efficacious for clinical applications, organ transplantation, and complex genomic research.

The scope of this market extends beyond simple cold storage, encompassing the development of innovative media formulations and automated monitoring systems that safeguard biospecimens from environmental stressors. As the medical community shifts toward personalized medicine and cell-based therapies, the reliance on robust biopreservation protocols has intensified. The industry acts as a foundational enabler for the global healthcare infrastructure, supporting the growing network of biobanks and the biopharmaceutical supply chain. With the continuous evolution of cryopreservation and vitrification techniques, the market continues to expand its reach, facilitating breakthroughs in chronic disease treatment and agricultural genetics.

Key Insights

• As per the analysis shared by our research analyst, the biopreservation market is projected to grow annually at a CAGR of around 14.40% over the forecast period (2026-2034).
• In terms of revenue, the market was valued at approximately USD 4.68 billion in 2025 and is expected to reach USD 24.57 billion by 2034.
• The market is driven by the rising prevalence of chronic diseases and the subsequent surge in clinical trials requiring high-integrity biospecimen storage.
• Based on the product, the equipment segment dominated the market with a share of over 70% in 2025 because of the high capital expenditure required for ultra-low temperature freezers and liquid nitrogen storage systems.
• Based on the application, the biobanking segment dominated the market with a share of approximately 45% because of the massive increase in public and private cord blood banking and the storage of samples for genomic research.
• Based on the end-user, the biobanks and gene banks segment dominated the market with a share of 40% as they serve as the primary repositories for biological assets used in personalized medicine and academic research.
• North America accounted for the largest market share of over 46% in 2025 because of its advanced healthcare infrastructure and the presence of a majority of the world’s leading biopharmaceutical companies.

Growth Drivers

• Expansion of Cell and Gene Therapy (CGT) Pipelines

The rapid commercialization of FDA-approved cell and gene therapies is a primary catalyst for market expansion. These advanced therapies are highly temperature-sensitive and require a seamless, GMP-compliant cold chain to maintain their therapeutic potency from the lab to the patient.

As more autologous and allogeneic treatments enter the clinical stage, the demand for specialized cryopreservation media and automated storage solutions has increased exponentially. This trend is compelling healthcare providers to invest in reliable biopreservation infrastructure to support the growing patient volume for oncology and rare disease treatments.

Restraints

• High Capital and Operating Costs

The implementation of advanced biopreservation systems involves significant initial investments in specialized equipment, such as vapor-phase liquid nitrogen freezers and automated cell processing systems. For many smaller research institutions and hospitals, these high entry costs represent a substantial barrier to adoption.

Furthermore, the ongoing operational expenses related to electricity consumption, liquid nitrogen refills, and stringent regulatory compliance add to the financial burden. These economic factors often lead to a slower adoption rate in budget-constrained environments, particularly in developing economies where healthcare funding is prioritized for primary care.

Opportunities

• Integration of Artificial Intelligence and IoT

The emergence of "smart" biobanking, which integrates AI-driven analytics and IoT sensors for real-time monitoring, presents a massive opportunity for market players. These technologies allow for predictive maintenance of freezers and precise tracking of sample temperature history, significantly reducing the risk of sample loss.

By automating the audit trails and inventory management processes, AI-integrated systems enhance the reliability of large-scale biobanks. This technological shift attracts high-value contracts from pharmaceutical companies that require guaranteed sample integrity for long-term clinical longitudinal studies.

Challenges

• Stability Issues and Technical Complexity

Maintaining the structural integrity of complex tissues and organs during the freezing and thawing process remains a significant technical challenge. Ice crystal formation and osmotic stress can cause irreversible cell damage, which limits the shelf life and efficacy of certain biological products.

Despite advancements in cryoprotective agents, finding the perfect balance between toxicity and preservation efficiency for different cell types is a persistent hurdle. Overcoming these biological limitations requires continuous R&D, which can be time-consuming and costly for manufacturers in a competitive landscape.

Report Scope

Market Segmentation

The biopreservation market is segmented by product, application, end-user, and region.

Based on Product, the biopreservation market is divided into subsegment equipment, media, accessories, and others. The equipment segment is currently the most dominant due to the heavy reliance on ultra-low temperature (ULT) freezers, cryogenic storage tanks, and automated liquid handling systems that form the backbone of biobanking infrastructure. The media segment is the second most dominant and is the fastest-growing subsegment, as it is a recurring consumable. The shift toward specialized, DMSO-free, and chemically defined media is driving this segment's value, as clinical-grade therapies require high-purity consumables to meet regulatory safety standards.

Based on Application, the biopreservation market is divided into subsegment regenerative medicine, biobanking, drug discovery, and others. The biobanking segment is the most dominant because it serves as the essential infrastructure for storing diverse biospecimens used in both clinical and research settings. Following this, the regenerative medicine segment is the second most dominant, driven by the explosion in stem cell research and the clinical application of tissue engineering. The demand for biopreservation in regenerative medicine is propelled by the need to maintain the "live" status of cells used in life-saving transplants and therapies.

Based on End-User, the biopreservation market is divided into subsegment biobanks, gene banks, hospitals, pharmaceutical & biotech companies, and others. Biobanks and gene banks are the dominant end-users, acting as the primary repositories for the global collection of biological samples used in population studies and personalized medicine. Pharmaceutical and biotech companies represent the second most dominant segment, as these entities increasingly internalize their storage capabilities to support their internal R&D pipelines and the manufacturing of temperature-sensitive biologics.

Recent Developments

• In November 2025, BioLife Solutions, Inc. inaugurated the Aby J. Mathew Center for Biopreservation Excellence at its expanded headquarters, focusing on advancing research in cryopreservation and clinical-grade media development.
• In October 2025, Cryoport, Inc. expanded its global reach by opening a 55,000-square-foot Global Supply Chain Center in France, specifically designed to enhance the temperature-controlled delivery of advanced therapies across Europe.
• In May 2025, Azenta, Inc. announced a strategic partnership with Form Bio to integrate AI-powered data analysis with their sequencing services, optimizing the way gene therapy samples are managed and preserved.
• In April 2025, BioLife Solutions acquired PanTHERA CryoSolutions, integrating proprietary Ice Recrystallization Inhibitor (IRI) technology into its portfolio to improve cell recovery rates post-thaw.

Regional Analysis

• North America to dominate the market

The North America region is expected to maintain its leading position in the biopreservation market due to its robust ecosystem of biotechnology firms and world-class research institutions. The United States, as the primary contributing country, hosts the highest number of clinical trials for cell and gene therapies globally, which creates a constant demand for high-end preservation solutions. Significant federal funding from organizations like the NIH and a well-established regulatory framework provided by the FDA further support market growth. Additionally, the region's early adoption of automated biobanking and the presence of major industry players like Thermo Fisher Scientific and BioLife Solutions ensure a high level of innovation. The focus on personalized medicine and strategic biosecurity reserves also drives the expansion of large-scale cryogenic facilities across the continent.

The Europe region represents a significant portion of the market, with Germany and the UK leading the way through harmonized biobanking regulations and a strong emphasis on sustainable "Green Lab" practices. The region's market is characterized by strict compliance with GDPR for sample data management and a shift toward energy-efficient storage equipment. Asia-Pacific is identified as the fastest-growing region, with China and India emerging as manufacturing hubs for biopharmaceuticals and vaccines. China's massive investment in genomic research and the construction of state-of-the-art biobanks are key drivers. Meanwhile, the Middle East and Africa are seeing gradual growth, supported by improving healthcare infrastructure and the establishment of new cord blood banks in urban centers.

Competitive Analysis

The global biopreservation market is dominated by players:

• Thermo Fisher Scientific Inc.
• BioLife Solutions, Inc.
• Merck KGaA
• Azenta, Inc. (formerly Brooks Automation)
• Cryoport, Inc.
• PHC Holdings Corporation
• MVE Biological Solutions
• Chart Industries, Inc.
• Taylor-Wharton
• Stirling Ultracold
• X-Therma Inc.
• Bio-Techne Corporation

The global biopreservation market is segmented as follows:

By Product

• Equipment
• Media
• Accessories
• Laboratory Information Management Systems (LIMS)

By Application

• Regenerative Medicine
• Biobanking
• Drug Discovery
• Clinical Trials

By End-User

• Biobanks and Gene Banks
• Hospitals
• Pharmaceutical & Biotech Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America